Allogene Therapeutics Income Statement (2018-2026) | ALLO

Income Statement Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.04M0.05M75.65M0.04M0.06M0.03M0.03M0.03M0.02M0.02M0.02M0.02M
Operating items
Research & Development (Quarter)
52.29M58.72M53.98M60.16M57.17M63.64M75.42M80.24M62.04M45.98M54.66M52.26M50.35M44.71M44.97M50.20M40.16M31.16M28.63M32.00M
Selling, General & Administrative (Quarter)
18.78M19.00M19.96M19.90M19.51M18.90M21.00M18.88M18.52M17.04M17.22M17.27M16.09M16.33M15.52M14.99M14.28M13.74M13.77M14.09M
Other Operating Expenses (Quarter)
13.24M4.99M10.73M2.38M
Operating Expenses (Quarter)
71.07M77.72M73.94M80.05M76.68M82.54M96.42M99.12M80.56M63.02M85.13M69.53M71.43M71.77M60.49M65.19M56.82M44.90M42.40M46.09M
Operating Income (Quarter)
-71.03M-77.67M1.71M-80.01M-76.62M-82.51M-96.39M-99.09M-80.54M-63.00M-85.11M-69.50M-71.43M-71.77M-60.49M-65.19M-56.82M-44.90M-42.40M-46.09M
EBIT (Quarter)
-71.03M-77.67M1.71M-80.01M-76.62M-82.51M-96.39M-99.09M-80.54M-63.00M-85.11M-69.50M-71.43M-71.77M-60.49M-65.19M-56.82M-44.90M-42.40M-46.09M
Non-operating items
Interest & Investment Income (Quarter)
0.62M0.39M0.19M0.49M0.32M1.00M2.76M2.06M3.78M6.21M6.26M5.43M4.99M6.71M3.03M5.52M6.19M3.93M3.66M3.57M
Other Non Operating Income (Quarter)
-0.53M-0.91M-1.81M0.92M-3.99M-2.73M-3.64M2.06M-2.47M-5.50M-6.93M-0.93M0.09M-1.12M-1.95M0.09M-0.04M-0.08M0.25M0.21M
Non Operating Income (Quarter)
0.09M-0.52M-1.62M1.41M-3.67M-1.73M-0.88M-0.88M3.78M0.71M-0.67M4.50M5.07M5.48M0.99M5.46M5.88M3.50M3.59M3.48M
Net income details
EBT (Quarter)
-146.94M-160.39M-0.01M-81.52M-109.12M-224.93M-100.54M-100.03M-113.00M-91.53M-72.84M-77.68M-191.98M-78.68M-57.54M-73.75M-76.28M-65.29M-39.06M-145.21M
Tax Provisions (Quarter)
Profit After Tax (Quarter)
-70.94M-78.19M-2.75M-78.61M-80.29M-85.73M-97.28M-99.97M-79.23M-60.85M-76.81M-65.00M-66.36M-66.29M-60.19M-59.60M-50.94M-41.12M-38.45M-43.06M
Income from Non-Controlling Interests (Quarter)
-0.23M-0.06M-2.17M-6.68M-2.22M-1.49M3.03M3.99M2.08M1.44M1.46M0.03M0.15M0.94M-0.25M0.13M-0.09M0.28M0.03M-0.45M
Income from Continuing Operations (Quarter)
-146.94M-160.39M-0.01M-81.52M-109.12M-224.93M-100.54M-100.03M-113.00M-91.53M-72.84M-77.68M-191.98M-78.68M-57.54M-73.75M-76.28M-65.29M-39.06M-145.21M
Consolidated Net Income (Quarter)
-146.94M-160.39M-0.01M-81.52M-109.12M-224.93M-100.54M-100.03M-113.00M-91.53M-72.84M-77.68M-191.98M-78.68M-57.54M-73.75M-76.28M-65.29M-39.06M-145.21M
Income towards Parent Company (Quarter)
-146.94M-160.39M-0.01M-81.52M-109.12M-224.93M-100.54M-100.03M-113.00M-91.53M-72.84M-77.68M-191.98M-78.68M-57.54M-73.75M-76.28M-65.29M-39.06M-145.21M
Net Income towards Common Stockholders (Quarter)
-146.94M-160.39M-0.01M-81.52M-109.12M-224.93M-100.54M-100.03M-113.00M-91.53M-72.84M-77.68M-191.98M-78.68M-57.54M-73.75M-76.28M-65.29M-39.06M-145.21M
Additional items
EPS (Basic) (Quarter)
-1.09-1.170.00-0.58-0.76-1.57-0.70-0.69-0.77-0.55-0.46-0.46-1.01-0.38-0.30-0.34-0.35-0.29-0.18-0.60
EPS (Diluted) (Quarter)
-1.09-1.170.00-0.58-0.76-1.57-0.70-0.69-0.77-0.55-0.46-0.46-1.01-0.38-0.30-0.34-0.35-0.29-0.18-0.60
Shares Outstanding (Quarter)
134.83M137.03M135.82M141.36M143.39M143.66M143.15M144.56M146.80M167.65M156.93M169.13M190.03M209.19M194.81M215.36M218.93M222.04M220.62M240.29M
Shares Outstanding (Diluted) (Quarter)
134.83M137.03M135.82M141.36M143.39M143.66M143.15M144.56M146.80M167.65M156.93M169.13M190.03M209.19M194.81M215.36M218.93M222.04M220.62M240.29M
EBITDA (Quarter)
-71.03M-77.67M1.71M-80.01M-76.62M-82.51M-96.39M-99.09M-80.54M-63.00M-85.11M-69.50M-71.43M-71.77M-60.49M-65.19M-56.82M-44.90M-42.40M-46.09M
Interest Expenses (Quarter)
76.53M83.12M1.90M2.00M32.81M143.42M6.90M3.00M36.24M34.74M-6.00M13.61M125.54M13.61M0.08M14.08M25.65M24.31M0.31M102.69M
Tax Rate (Quarter)